Live Feeds
● TRACKER Updated 5d ago · 6 sources tracked

Insilico's co-CEO hopes 'we might have a chance to stop biological aging'

Insilico Medicine began dosing the first patient on September 9, 2026, for the GENESIS-IPF-3 trial, the first Phase III study of a generative AI-driven drug. While the candidate targets lung disease, early data suggests it may slow or reverse biological aging. The company's co-CEO believes this technology provides a chance to stop biological aging. Researchers are utilizing proteomic aging clocks in Phase 2a trials to assess these geroprotective effects simultaneously with primary disease treatment.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Insilico Medicine began dosing the first patient in the GENESIS-IPF-3 Phase III trial on September 9, 2026.
  • ✓ The drug candidate was designed using generative AI.
🛡️ Source Corroboration: 6 independent reporting domains (80% confidence) ⏱ Read time: ~2 min

What changed

Insilico Medicine initiated the first Phase III trial for a generative AI-driven innovative drug.

Live updates

  1. Insilico Medicine Starts Phase III Trial for AI-Designed Drug

    Insilico Medicine began dosing the first patient on September 9, 2026, for the GENESIS-IPF-3 trial, the first Phase III study of a generative AI-driven drug. While the candidate targets lung disease, early data suggests it may slow or reverse biological aging. The company's co-CEO believes this technology provides a chance to stop biological aging. Researchers are utilizing proteomic aging clocks in Phase 2a trials to assess these geroprotective effects simultaneously with primary disease treatment.

    Why it matters

    Generative AI is being used to accelerate drug discovery by designing molecules for specific targets. This approach aims to reduce the time and cost of clinical development. The current focus on idiopathic pulmonary fibrosis also explores the intersection of disease treatment and longevity science.

    What is confirmed

    • Insilico Medicine began dosing the first patient in the GENESIS-IPF-3 Phase III trial on September 9, 2026.
    • The drug candidate was designed using generative AI.

    Still unconfirmed

    • Insilico's co-CEO hopes the company might have a chance to stop biological aging.

    What to watch next

    • Results from the GENESIS-IPF-3 Phase III trial
    • Peer-reviewed data confirming the drug's effect on biological age
    Sources used for this update (6)
    1. The New York Times — Early Data Indicates an A.I.-Generated Drug Could Slow Aging
    2. Nature — Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
    3. News-Medical — AI-designed drug candidate reverses biological age in clinical study
    4. fortune.com — Insilico's co-CEO hopes 'we might have a chance to stop biological aging'
    5. USA Today — A lung disease drug also might slow aging. What researchers found
    6. www.finanznachrichten.de — Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
    confidence 80%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community